Middle East & North Africa | Prevalence of HIV, total (% of population ages 15-49)
Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source
Middle East & North Africa | Prevalence of HIV, total (% of population ages 15-49)
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990 0.1
1991 0.1002887
1992 0.10055649
1993 0.10106859
1994 0.10186635
1995 0.10262048
1996 0.10366092
1997 0.1053155
1998 0.10679635
1999 0.1082599
2000 0.10914559
2001 0.10949104
2002 0.10958589
2003 0.10927723
2004 0.10858819
2005 0.10766949
2006 0.10709219
2007 0.10654507
2008 0.10602207
2009 0.10551913
2010 0.10500377
2011 0.10449093
2012 0.1042609
2013 0.10374183
2014 0.1035028
2015 0.10325197
2016 0.10486099
2017 0.10459884
2018 0.10432987
2019 0.10435234
2020 0.1040623
2021 0.10478504
2022
Middle East & North Africa | Prevalence of HIV, total (% of population ages 15-49)
Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source